Latest news with #CTDILD
Medscape
5 days ago
- Health
- Medscape
ILD Survival Differs Despite Similar CT Patterns
TOPLINE: Despite patients sharing a usual interstitial pneumonia (UIP) pattern on lung CT scans, patients with connective tissue disease-related interstitial lung disease (CTD-ILD) demonstrated a slower decline in lung function and longer transplant-free survival than those with idiopathic pulmonary fibrosis (IPF). However, varying results were reported for those with fibrotic hypersensitivity pneumonitis (FHP). METHODOLOGY: Researchers assessed whether the rate of decline in forced vital capacity (FVC) and transplant-free survival differ among patients with any major subtype of ILD despite sharing a similar UIP pattern on CT. They analyzed data of 860 patients (median follow-up duration, 18.6 months) from a PF registry and 1578 patients (median follow-up duration, 17.9 months) patients from a meta-cohort of ILD research studies; the patients were primarily from the US and UK who were diagnosed with either IPF, FHP, or CTD-ILD. CT was performed and based on the fibrotic pattern, patients were categorized into five groups: IPF (reference), FHP without a UIP pattern, FHP with a UIP pattern, CTD without a UIP pattern, and CTD with a UIP pattern. The annual rate of decline in FVC and 5-year transplant-free survival were determined. TAKEAWAY: Patients with CTD-ILD with a UIP CT pattern showed a significantly slower rate of decline in FVC than those with IPF in both the registry cohort (-34.4 vs -158.4 mL/y; P = .008) and meta-cohort (-53.1 vs -185.9 mL/y; P < .0001). In the registry cohort, patients with CTD-ILD with (hazard ratio [HR], 0.50; 95% CI, 0.29-0.85) and without (HR, 0.28; 95% CI, 0.17-0.45) a UIP CT pattern had a lower risk for 5-year transplant-free mortality than those with IPF. This finding was also true for the meta-cohort. In both cohorts, the rate of decline in FVC in patients with FHP with a UIP CT pattern did not significantly differ from that in patients with IPF. However, those with FHP without a UIP CT pattern showed a slower rate of decline in FVC in the meta-cohort. Patients with FHP without a UIP CT pattern demonstrated a significantly better rate of transplant-free survival than those with IPF in both cohorts, while those with a UIP pattern showed improved survival only in the meta-cohort. IN PRACTICE: 'Our findings may have important clinical implications and argue against extrapolating clinical outcomes of IPF to other ILDs with a UIP CT pattern, particularly when estimating prognosis or devising management plans,' the authors wrote. SOURCE: This study was led by John S. Kim, MD, University of Virginia School of Medicine, Charlottesville, Virginia. It was published online on June 8, 2025 in Thorax. LIMITATIONS: The PFF-PR cohort had a considerably smaller FHP-UIP subgroup, potentially limiting the statistical power for FHP analyses. The research cohorts had uneven proportions of patients with ILD subtypes, potentially affecting the replication of the findings. Most participants self-identified as White and were from the US, introducing potential selection bias and limiting generalizability. DISCLOSURES: The study did not receive any specific funding. The lead author was supported by grants from the National Institute of Heart, Lung, and Blood Institute. Multiple authors disclosed receiving consulting fees, speaker honoraria, personal fees, grants, and research support from and having other ties with various pharmaceutical companies, including Boehringer Ingelheim, Roche/Genentech, and others. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Globe and Mail
30-06-2025
- Business
- Globe and Mail
GlaxoSmithKline, Actelion, Prometheus Biosciences, Eric Matteson, Genentech, Inc., Boehringer Ingelheim
DelveInsight's 'CTD-ILD Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the CTD-ILD, historical and forecasted epidemiology as well as the CTD-ILD market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan. The latest healthcare forecast report provides an in-depth analysis of CTD-ILD, offering comprehensive insights into the CTD-ILD revenue trends, prevalence, and treatment landscape. The report delves into key CTD-ILD statistics, highlighting the current and projected market size, while examining the efficacy and development of emerging CTD-ILD therapies. Additionally, we cover the landscape of CTD-ILD clinical trials, providing an overview of ongoing and upcoming studies that are poised to shape the future of CTD-ILD treatment. This report is an essential resource for understanding the market dynamics and the evolving therapeutic options within the CTD-ILD space. The CTD-ILD market size was valued ~USD 1,498 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034) In 2023, the United States held the largest market share for Connective Tissue Disease associated with Interstitial Lung Disease (CTD-ILD), contributing approximately 70% of the total market size across the 7MM. This was significantly higher compared to other key markets, including the EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan. In 2023, Germany recorded the largest market size for Connective Tissue Disease associated with Interstitial Lung Disease (CTD-ILD) among EU countries, reaching nearly USD 84 million, while Spain had the smallest market size at USD 38 million. Japan's market size for Connective Tissue Disease associated with Interstitial Lung Disease (CTD-ILD) was approximately USD 136 million in 2023, representing 9% of the total market across the 7MM. Key CTD-ILD Companies: GlaxoSmithKline, Actelion, Prometheus Biosciences, Eric Matteson, Genentech, Inc., Boehringer Ingelheim Pharmaceuticals, and others Key CTD-ILD Therapies: Belimumab, bosentan, Tulisokibart, Rituximab, Vixarelimab, OFEV, Belimumab, GSK1550188 (BENLYSTA), and others The CTD-ILD market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage CTD-ILD pipeline products will significantly revolutionize the CTD-ILD market dynamics. According to DelveInsight's evaluation, the total prevalent cases of Interstitial Lung Disease (ILD) in the 7MM were approximately 1,662,000 in 2023. In 2023, the United States recorded the highest number of diagnosed prevalent cases of Connective Tissue Disease associated with Interstitial Lung Disease (CTD-ILD), approximately 132,000, with numbers anticipated to increase in the future. Within Europe, the UK reported the highest number of diagnosed prevalent cases of CTD-ILD in 2023, approximately 27,000, followed by Germany with 25,000 cases. In contrast, Spain had the lowest prevalence, with around 11,000 cases. In 2023, Japan reported approximately 68,000 diagnosed prevalent cases of Connective Tissue Disease associated with Interstitial Lung Disease (CTD-ILD), representing around 23% of the total cases across the 7MM. In the US in 2023, type-specific diagnosed cases of CTD-ILD were highest for pSS-ILD (approximately 38,000), followed by SSc-ILD (around 31,000), Other CTD-ILDs (roughly 30,000), RA-ILD (about 20,000), DM-ILD/PM-ILD (close to 8,000), and SLE-ILD (nearly 5,000). Connective Tissue Disease associated with Interstitial Lung Disease Overview Connective Tissue Disease (CTD)-associated Interstitial Lung Disease (ILD) refers to a group of lung disorders that occur as a result of underlying connective tissue diseases. These diseases, such as rheumatoid arthritis, systemic lupus erythematosus, scleroderma, and polymyositis, can cause inflammation and scarring in the lungs, leading to ILD. This condition results in impaired lung function, breathing difficulties, and decreased oxygen levels. The damage is often progressive and can lead to respiratory failure if left untreated. Early diagnosis and management are crucial to managing symptoms and slowing disease progression. Treatment typically involves immunosuppressive medications and management of the underlying CTD. CTD-ILD Epidemiology The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends. Connective Tissue Disease associated with Interstitial Lung Disease Epidemiology Segmentation: The CTD-ILD market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into: Download the report to understand which factors are driving CTD-ILD epidemiology trends @ CTD-ILD Epidemiology Forecast CTD-ILD Drugs Uptake and Pipeline Development Activities The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the CTD-ILD market or expected to get launched during the study period. The analysis covers CTD-ILD market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share. The report also covers the CTD-ILD Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies. CTD-ILD Therapies and Key Companies Belimumab: GlaxoSmithKline bosentan: Actelion Tulisokibart: Prometheus Biosciences Rituximab: Eric Matteson Vixarelimab: Genentech, Inc. OFEV: Boehringer Ingelheim Pharmaceuticals, Inc. Belimumab, GSK1550188 (BENLYSTA): GlaxoSmithKline plc. Connective Tissue Disease associated with Interstitial Lung Disease Market Drivers Increasing Prevalence of CTD-ILD Advances in Diagnostic Techniques Emergence of Novel Therapies Rising Awareness Among Healthcare Providers Aging Population Regulatory Approvals for Targeted Treatments Supportive Healthcare Policies Connective Tissue Disease associated with Interstitial Lung Disease Market Barriers High Cost of Treatment Limited Drug Approvals Challenges in Early Diagnosis Heterogeneity of CTD-ILD Side Effects of Current Treatments Lack of Awareness in Emerging Markets Inconsistent Clinical Guidelines Scope of the Connective Tissue Disease associated with Interstitial Lung Disease Market Report Study Period: 2020–2034 Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan] Key CTD-ILD Companies: GlaxoSmithKline, Actelion, Prometheus Biosciences, Eric Matteson, Genentech, Inc., Boehringer Ingelheim Pharmaceuticals, and others Key CTD-ILD Therapies: Belimumab, bosentan, Tulisokibart, Rituximab, Vixarelimab, OFEV, Belimumab, GSK1550188 (BENLYSTA), and others CTD-ILD Therapeutic Assessment: CTD-ILD current marketed and CTD-ILD emerging therapies CTD-ILD Market Dynamics: CTD-ILD market drivers and CTD-ILD market barriers Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies Table of Contents 1. CTD-ILD Market Report Introduction 2. Executive Summary for CTD-ILD 3. SWOT analysis of CTD-ILD 4. CTD-ILD Patient Share (%) Overview at a Glance 5. CTD-ILD Market Overview at a Glance 6. CTD-ILD Disease Background and Overview 7. CTD-ILD Epidemiology and Patient Population 8. Country-Specific Patient Population of CTD-ILD 9. CTD-ILD Current Treatment and Medical Practices 10. CTD-ILD Unmet Needs 11. CTD-ILD Emerging Therapies 12. CTD-ILD Market Outlook 13. Country-Wise CTD-ILD Market Analysis (2020–2034) 14. CTD-ILD Market Access and Reimbursement of Therapies 15. CTD-ILD Market Drivers 16. CTD-ILD Market Barriers 17. CTD-ILD Appendix 18. CTD-ILD Report Methodology 19. DelveInsight Capabilities 20. Disclaimer 21. About DelveInsight About DelveInsight DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach. Media Contact Company Name: DelveInsight Contact Person: Gaurav Bora Email: Send Email Phone: +14699457679 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
